120 related articles for article (PubMed ID: 23575040)
1. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.
von Websky A; Reich K; Steinkraus V; Breuer K
J Dtsch Dermatol Ges; 2013 Jul; 11(7):677-8. PubMed ID: 23575040
[No Abstract] [Full Text] [Related]
2. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
[No Abstract] [Full Text] [Related]
3. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
[No Abstract] [Full Text] [Related]
4. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
Wieder S; Maurer M; Lebwohl M
Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
[TBL] [Abstract][Full Text] [Related]
5. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
[No Abstract] [Full Text] [Related]
6. Omalizumab. An option in vernal keratoconjunctivitis?
Sánchez J; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
[No Abstract] [Full Text] [Related]
7. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of a bullous urticaria with omalizumab.
Ozturk AB; Kocaturk E; Ozturk E
Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
[No Abstract] [Full Text] [Related]
9. Successful treatment of severe delayed pressure angio-oedema with omalizumab.
Rodríguez-Rodríguez M; Antolin-Amerigo D; Barbarroja-Escudero J; Sánchez-González MJ; Alvarez-Mon M
Allergol Immunopathol (Madr); 2014; 42(1):78-80. PubMed ID: 23395519
[No Abstract] [Full Text] [Related]
10. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
11. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
12. Imported fire ant rush desensitization using omalizumab and a premedication regimen.
Tille KS; Parker AL
Ann Allergy Asthma Immunol; 2014 Nov; 113(5):574-6. PubMed ID: 25216971
[No Abstract] [Full Text] [Related]
13. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
Wu KCP; Jabbar-Lopez ZK
J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
[TBL] [Abstract][Full Text] [Related]
14. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
Cavelti-Weder C; Muggli B; Keller C; Babians-Brunner A; Biason-Lauber A; Donath MY; Schmid-Grendelmeier P
Diabetes Care; 2012 Jun; 35(6):e41. PubMed ID: 22619293
[No Abstract] [Full Text] [Related]
15. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
Sánchez-Ramón S; Eguíluz-Gracia I; Rodríguez-Mazariego ME; Paravisini A; Zubeldia-Ortuño JM; Gil-Herrera J; Fernández-Cruz E; Suárez-Fernández R
J Investig Allergol Clin Immunol; 2013; 23(3):190-6. PubMed ID: 23967758
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab for treatment of allergic rhinitis.
Vashisht P; Casale T
Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
[TBL] [Abstract][Full Text] [Related]
17. Promising option in the prevention of idiopathic anaphylaxis: omalizumab.
Demirtürk M; Gelincik A; Colakoğlu B; Dal M; Büyüköztürk S
J Dermatol; 2012 Jun; 39(6):552-4. PubMed ID: 22390871
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
[No Abstract] [Full Text] [Related]
19. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
[TBL] [Abstract][Full Text] [Related]
20. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light.
Duchini G; Bäumler W; Bircher AJ; Scherer K
Photodermatol Photoimmunol Photomed; 2011 Dec; 27(6):336-7. PubMed ID: 22092741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
